Cetaphil

Galderma Group AG's 2025 annual report gives its registered office as Zählerweg 10, Zug, Switzerland, with shares listed on the SIX Swiss Exchange (ticker GALD) since March 22, 2024, and lists Galderma Canada Inc. and G. Production Inc. as wholly owned Canadian subsidiaries. No shareholder holds a majority: the only notified block is a 34.6 percent group of EQT funds, Abu Dhabi Investment Authority, GIC of Singapore and L'Oréal, so the mix follows the Swiss headquarters and listing venue, with a small OTHER share estimated for the Gulf and Singapore sovereign funds inside that group. Corporations Canada returned no federal record for Galderma, consistent with the report placing Galderma Canada Inc.'s seat in Saint John, New Brunswick; the provincial registry could not be checked.

• Galderma 2025 Annual Report filing “The Company's registered offices are at Zählerweg 10, CH-6300 Zug, Switzerland. Its shares have been listed on the SIX Swiss Exchange in Switzerland (ISIN: CH1335392721, ticker symbol: GALD, valor number: 133.539.272) since March 22, 2024.”
• Galderma 2025 Annual Report filing “82,374,839 registered shares, relating to 34.626% of the voting rights in the Company”
• eCommerce Solutions On-Demand | Salesforce Privacy Policy vendor_statement “Galderma Canada Inc. (the "Company") is committed to ensuring the privacy of those who use its products”
• Search for a Federal Corporation - Online Filing Centre - Corporations Canada registry “0 results were found”

Galderma's manufacturing page and 2025 annual report both say the Baie-D'Urfé, Quebec plant, its largest at over 180 million units a year, is the home of global production for Cetaphil and its main plant in North America. The same report says Galderma is expanding US production for select Cetaphil products through US-based partners, so a minority US share is estimated; no per-product split is published. The CANADA List corroborates Canada and USA as the manufacturing countries.

• MANUFACTURING | Galderma vendor_statement “Our largest production site, at Baie-D'Urfé, Canada, is focused on the global supply of Cetaphil, with additional production of OTC and prescription medicine for the U.S. market.”
• Galderma 2025 Annual Report filing “We are also expanding U.S. production for select Cetaphil products, strengthening local supply and further increasing our U.S. market presence.”
• Canada | Galderma vendor_statement “Located in Baie-D'Urfé (on the western tip of the Island of Montreal), the facility is considered to be Galderma's main manufacturing plant in North America servicing clients worldwide.”
• The CANADA List directory “Owned by Galderma (Switzerland). Some production in Canada, largely in Ontario.”

Galderma's Canada page gives Galderma Canada Inc.'s head office as 55 Commerce Valley Drive W, Thornhill, Ontario, and G. Production Inc.'s plant at 19400 TransCanada Highway, Baie-D'Urfé, Quebec, which together cover the Canadian sales team and the production workforce behind the brand. Global brand management sits with the parent in Zug and its US organization, so a small share is allocated to each; no headcount by country is published for the brand.

• Canada | Galderma vendor_statement “GALDERMA CANADA INC (HEAD OFFICE) 55 Commerce Valley Drive W, Suite 400, Thornhill, ON, L3T 7V9”
• Canada | Galderma vendor_statement “GALDERMA PRODUCTION INC. (BAIE-D'URFÉ, QC) 19400 TransCanada Highway, Baie-D'Urfé (Quebec) H9X 3S4”

Cetaphil formulas rest on petrolatum, glycerin, fatty alcohols, niacinamide and plastic packaging, commodity inputs that a Quebec plant most plausibly draws from US and Canadian chemical suppliers, with specialty actives from European and Asian makers. Galderma publishes no sourcing breakdown, so this split is an estimate.

• MANUFACTURING | Galderma vendor_statement “Alongside our in-house operations, we also outsource the production of selected products and formulations.”